
Osteoarthritis
High/low molecular weight HA injection vs. placebo in knee OA
Rheumatol Int. 2006 Feb;26(4):325-3078 patients with a confirmed diagnosis of knee osteoarthritis were randomized to receive intra-articular injections of either a hyaluronan product (Orthovisc), a high-molecular-weight hyaluronan product (Synvisc), or placebo, weekly. The purpose of the study was to compare the efficacy of these different formulations of hyaluronic acid. The results of this study indicated improvements in pain, function and global assessments for all three groups; however, the hyaluronic acid groups were not clinically superior to the placebo treatment 6 months after treatment initiation for pain and there were no differences between the hyaluronic acid preparations.
Unlock the full article
Get unlimited access to OrthoEvidence with a free trial
Start TrialCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or continue reading this full article
Register Now

Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.